UPDATE: UBS Starts MetLife (MET) at Buy; Now Only Truly Global Play with Recent Alico Acquisition
Tweet Send to a FriendGet Alerts MET Hot Sheet
Price: $45.41 +1.14%
Rating Summary:
10 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
10 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade MET Now!
(Updated - July 18, 2012 11:35 AM EDT)
UBS initiates coverage on MetLife (NYSE: MET) with a Buy. PT $43.00.
Analyst, Suneet Kamath, said, "We believe investor concerns are largely around the timing and eventual size of capital return due to regulatory uncertainty. Although the lack of buyback is a near-term ROE drag, we argue that at 0.65x P/B and a current 11% ROE (and potentially to 12%+ longer-term), we find MET’s risk/reward compelling. Further, we argue MET’s long-term ROE guidance may prove conservative, providing a potential upside surprise."
"Due to the Alico acquisition, MET is the only truly global play in our coverage universe. We expect its exposure to fast growing and high return emerging markets, which MET expects to grow to 20%+ of earnings by 2016 from 14% now, should lift the company’s overall ROE outlook over time."
For an analyst ratings summary and ratings history on MetLife click here. For more ratings news on MetLife click here.
Shares of MetLife closed at $30.84 yesterday, with a 52 week range of $25.61-$42.86.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
UBS initiates coverage on MetLife (NYSE: MET) with a Buy. PT $43.00.
Analyst, Suneet Kamath, said, "We believe investor concerns are largely around the timing and eventual size of capital return due to regulatory uncertainty. Although the lack of buyback is a near-term ROE drag, we argue that at 0.65x P/B and a current 11% ROE (and potentially to 12%+ longer-term), we find MET’s risk/reward compelling. Further, we argue MET’s long-term ROE guidance may prove conservative, providing a potential upside surprise."
"Due to the Alico acquisition, MET is the only truly global play in our coverage universe. We expect its exposure to fast growing and high return emerging markets, which MET expects to grow to 20%+ of earnings by 2016 from 14% now, should lift the company’s overall ROE outlook over time."
For an analyst ratings summary and ratings history on MetLife click here. For more ratings news on MetLife click here.
Shares of MetLife closed at $30.84 yesterday, with a 52 week range of $25.61-$42.86.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Starts Insmed (INSM) at Buy
- UPDATE: Deal With Cigna (CI) Does More than Remove Overhang; UBS Upgrades Catamaran (CTRX) to Buy
- Oxford Industries (OXM) Tops Q1 EPS by 4c, Trims Top-End of FY13 Revs Outlook
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBS, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
